OCCAM Immune

We are excited to launch OCCAM Immune, an Academic Research Organization providing streamlined #ImmuneMonitoring services to the pharma and biotech industry for clinical studies. Check out the immune monitoring as a service options we provide here >>> occam-immune.com

16-channel imaging of Ovarian Serous Cystadenocarcinoma, acquired on the Orion Spatial Biology platform. 🌟 Image is courtesy of Zhihong Chen and custody of Human Immune Monitoring Center, @Occamimmune, @IcahnMountSinai. #SpatialBiology #SpatialProteomics #OvarianCancer

Happy Holidays from the OCCAM Immune Team! 🎄 Thank you to all our partners and supporters for an amazing year. We’re excited for what’s ahead in 2025 and look forward to continuing this journey together. Wishing you a joyful holiday season! #HappyHolidays #Immunology

Excited to see that I rank among the highest cited people in the field of immunology and medicine. Proud of our work! #researcher #research #immunology #medicine #mountsinai #dermatology #skin #disease #translational #eczema #allergy #alopecia #treatment #inflammation #aging

Excited to announce that our CEO Erik Wambre, will be presenting "Immunophenotypes of Food Allergy & Responses to Immunotherapy Across the Life Course" Friday Nov 22 at the @EAACI_HQ FAAM-EUROBAT conference in Athens, Greece! Reach out if you'd like to meet—we’d love to connect!

DM if you'd like to meet the @OCCAMimmune team at the 'Next Generation Immunotherapy Discoveries' symposium Oct 3. We'd love to introduce our custom immune profiling capabilities to investigators & industry representatives planning clinical trials of cutting-edge immunotherapy.

JOIN US in-person at the 'Next Generation Immunotherapy Discoveries' Symposium, Oct 3rd in NYC, a great opportunity to meet CEO @ErikWambre & discuss cutting edge immune monitoring for clinical studies of new immunotherapies at the lunch or cocktail reception:

@ovanoekelen @CellRepMed Explore our full range of cutting-edge technologies for immunophenotyping patient responses to new immunotherapies to reveal how they work here >>> occam-immune.com.

@ovanoekelen @CellRepMed Iberdomide is a CELMoD: a new class of immunomodulatory drugs for treating myeloma. We employed standardized mass cytometry to show that Iberdomide enhances effector T and NK cells, offering new mechanistic insights into how Iberdomide boosts innate and adaptive tumor immunity.

Discover how the @Occamimmune mass cytometry panel helped Samir Parekh and @ovanoekelen uncover how Iberdomide activates immune cells to fight cancer in the bone marrow of patients with relapsed/refractory #MultipleMyeloma. Study in @CellRepMed 👇 loom.ly/UM5gtxk

@AllergyEaaci By unveiling an immunotherapy's mechanism of action, our antigen-specific T cell assays pave the way for targeted & effective treatments. More info on the cutting-edge immune monitoring services we provide to support immunotherapy clinical trials here >>> occam-immune.com

Check out our paper in @AllergyEaaci! Our antigen-specific T cell assays track the key changes in peanut-specific T cells during treatment, revealing the precise immune responses that underpin the immunotherapy's success in combatting #PeanutAllergy. loom.ly/FTcfMJ8

Meet @DrTomMarron, a pioneer of mechanistic clinical trials of cancer immunotherapy. Read about how Tom & @MiriamMerad's TARGET and INTERACT programs integrate immune profiling to provide actionable insights into how to treat cancer and other diseases >>> loom.ly/QxEyzfE

At @Occamimmune, we're expanding our #ImmuneMonitoring capabilities with brand-new, state-of-the-art facilities at the heart of Manhattan. We look forward to welcoming you to our new space at 619 West 54th St. and advancing immunotherapy and translational research together!

New from Samir Parekh, @ovanoekelen, and colleagues: Iberdomide increases innate and adaptive immune cell subsets in the bone marrow of patients with relapsed/refractory multiple myeloma: Cell Reports Medicine cell.com/cell-reports-m… @IcahnMountSinai #MultipleMyeloma